Publications / Posters :: ContraFect Corporation (CFRX)

Publications / Posters

Technology

Home
Technology
Publications / Posters

Publications

Direct Lytic Agents: Novel, Rapidly Acting Potential Antimicrobial Treatment Modalities for Systemic Use in the Era of Rising Antibiotic Resistance

Frontiers in Microbiology, March 2022, Volume 13, Article 841905

Exebacase in Addition to Daptomycin against MRSA

Antimicrobial Agents & Chemotherapy, November 2021, Volume 65, Issue 11

Exebacase Is Active In Vitro in Pulmonary Surfactant and Is Efficacious Alone and Synergistic with Daptomycin in a Mouse Model of Lethal Staphylococcus aureus Lung Infection

Antimicrobial Agents & Chemotherapy, September 2021, Volume 65, Issue 9

Activity of Lysin CF-296 Alone and in Addition to Daptomycin in a Rat Model of Experimental Methicillin-Resistant Staphylococcus aureus Osteomyelitis

Antimicrobial Agents & Chemotherapy, June 2021, Volume 65, Issue 6.

Efficacy assessment of lysin CF-296 in addition to daptomycin or vancomycin against Staphylococcus aureus in the murine thigh infection model

Journal of Antimicrobial Chemotherapy, July 5, 2021.

Determination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal Activity

Journal of Clinical Microbiology, July 2021, Volume 59, Issue 7

Development of a Broth Microdilution Method for Exebacase Susceptibility Testing

Antimicrobial Agents & Chemotherapy, July 2021, Volume 65, Issue 7

Arthroscopic “Debridement and Implant Retention” With Local Administration of Exebacase (Lysin CF-301)

Frontiers in Medicine, May 2021, Volume 8, Article 550853

Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis

The Journal of Clinical Investigation, Volume 130, Issue 7, July 1, 2020

Effect of the Lysin Exebacase on Cardiac Vegetation Progression in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Endocarditis as Determined by Echocardiography

Antimicrobial Agents & Chemotherapy, July 2020, Volume 64, Issue 7

Posters

Locally Delivered Antistaphylococcal Lysins Exebacase or CF-296 is Active in Methicillin-Resistant Staphylococcus aureus Implant-associated Osteomyelitis

Locally Delivered Antistaphylococcal Lysins Exebacase or CF-296 is Active in Methicillin-Resistant Staphylococcus aureus Implant-associated Osteomyelitis

Presented at ASM Microbe 2022, June 12, 2022

Lysin Exebacase Has a Low Propensity for Resistance Development and Suppresses the Emergence of Resistance to Anti-Staphylococcal Antibiotics

Lysin Exebacase Has a Low Propensity for Resistance Development and Suppresses the Emergence of Resistance to Anti-Staphylococcal Antibiotics

Presented at ASM Microbe 2022, April 23, 2022

Lysin CF-370 exhibits a low propensity for decreased susceptibility in Gram-negative (GN) ESKAPE pathogens

Lysin CF-370 exhibits a low propensity for decreased susceptibility in Gram-negative (GN) ESKAPE pathogens

Presented at ECCMID 2022, April 23, 2022

Lysin CF-370 suppresses in vitro resistance in Pseudomonas aeruginosa to meropenem, tobramycin and levofloxacin

Lysin CF-370 suppresses in vitro resistance in Pseudomonas aeruginosa to meropenem, tobramycin and levofloxacin

Presented at ECCMID 2022, April 23, 2022

Direct lytic agents, a novel family of antimicrobial agents, have a low propensity for decreased susceptibility in Gram-negative pathogens associated with airway infection in Cystic Fibrosis

Direct lytic agents, a novel family of antimicrobial agents, have a low propensity for decreased susceptibility in Gram-negative pathogens associated with airway infection in Cystic Fibrosis

Presented at ECCMID 2022, April 23, 2022

In vitro activity of exebacase against contemporary beta-haemolytic streptococci recovered from US patients with bloodstream infections

In vitro activity of exebacase against contemporary beta-haemolytic streptococci recovered from US patients with bloodstream infections

Presented at ECCMID 2022, April 23, 2022

Evaluation of the broth microdilution MIC method for exebacase against 100 beta-haemolytic streptococci

Evaluation of the broth microdilution MIC method for exebacase against 100 beta-haemolytic streptococci

Presented at ECCMID 2022, April 23, 2022

Assessment of exebacase MIC reproducibility: Thirty S. aureus isolates tested at three sites using three different commercial media lots

Assessment of exebacase MIC reproducibility: Thirty S. aureus isolates tested at three sites using three different commercial media lots

Presented at ECCMID 2022, April 23, 2022

Direct Lytic Agents (DLAs), a Novel Family of Antimicrobial Agents, Exert Potent in vitro Bactericidal Activity Against Gram-negative (GN) Pathogens Which Cause Pulmonary Infections in CF Patients, Including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Achromobacter xylosoxidans

Direct Lytic Agents (DLAs), a Novel Family of Antimicrobial Agents, Exert Potent in vitro Bactericidal Activity Against Gram-negative (GN) Pathogens Which Cause Pulmonary Infections in CF Patients, Including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Achromobacter xylosoxidans

Presented at North American Cystic Fibrosis Conference 2021, November 2, 2021

In vitro Activity of Exebacase (CF-301) against Staphylococcus aureus Causing Bacteremia in the United States, Including Multidrug-Resistant Subsets

In vitro Activity of Exebacase (CF-301) against Staphylococcus aureus Causing Bacteremia in the United States, Including Multidrug-Resistant Subsets

Presented at ID Week 2021, September 29, 2021

1
2
3
4
5
6
Next »